Insmed announces CFO transition: what it means for Insmed stock and USD 1.25 billion guidance

Published on 10/07/2026 at 02:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 425.49 million, 7.59 percent above consensus. Insmed stock had a EUR 93.45 prior close on October 5, 2026.

INSM, US4576693075, Illustration mit AI erstellt.

Insmed (ISIN US4576693075) reaffirmed fiscal 2026 BRINSUPRI revenue guidance of USD 1.25 billion to USD 1.40 billion as CFO Sara Bonstein prepares to leave on October 30, 2026. According to Insmed on October 5, 2026, Bonstein will remain CFO until that date while the company searches for her successor.

Guidance holds through CFO change

The company also reaffirmed fiscal 2026 ARIKAYCE revenue guidance of USD 450 million to USD 470 million. That leaves the commercial outlook intact while management changes at the finance function, making execution against the BRINSUPRI launch the central operating test for the rest of the year.

Insmed's second-quarter 2026 revenue was USD 425.49 million, while the consensus figure cited by MarketBeat was USD 395.50 million. The result was USD 29.99 million higher, equal to 7.59 percent above consensus, while reported diluted earnings per share were a loss of USD 0.06 compared with a consensus loss of USD 0.67.

Launch revenue changes the mix

The second-quarter figures show why BRINSUPRI matters more to the investment case. BRINSUPRI generated USD 309.20 million in second-quarter 2026 revenue, while ARIKAYCE contributed USD 116.30 million, according to Insmed's second-quarter earnings materials. BRINSUPRI revenue increased 49.00 percent from the first quarter, whereas ARIKAYCE revenue increased 8.00 percent from the second quarter of 2025.

The comparison also highlights the remaining risk: the guidance range depends on continued commercial execution rather than earnings profitability. Insmed reported a second-quarter 2026 net loss of USD 13.24 million and operating cash flow of negative USD 88.83 million, although both figures were less negative than in the first quarter of 2026.

Stock reference stays below yearly high

Insmed's market capitalization was USD 22.8 billion as of October 6, 2026. Its 52-week range was USD 90.39 to USD 212.75 on the same date, placing the equity closer to its yearly low than its yearly high and leaving the revenue outlook as the clearest quantified operating counterweight.

Next results arrive October 29

Insmed has scheduled its third-quarter 2026 financial results for October 29, 2026. The next report will give investors a fresh test of BRINSUPRI demand, ARIKAYCE sales and cash use against the reaffirmed full-year ranges.

The prior close at Lang & Schwarz was EUR 93.45 on October 5, 2026, while the quote page carried a dormant October 6 reference. The further course of trading is shown by the continuously updated real-time quote of Insmed stock.